These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
659 related items for PubMed ID: 35772665
1. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L, Pautier P, Ledermann JA, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Colombo N, Park-Simon TW, Tamura K, Sonke GS, Freimund AE, Lee CK, Pujade-Lauraine E. Ann Oncol; 2022 Oct; 33(10):1021-1028. PubMed ID: 35772665 [Abstract] [Full Text] [Related]
2. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial. Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marmé F, Lindemann K, Colombo N, Mądry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-Pérez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A, OReO/ENGOT-ov38 investigators. Ann Oncol; 2023 Dec; 34(12):1152-1164. PubMed ID: 37797734 [Abstract] [Full Text] [Related]
3. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinoza D, Joly F, Pujade-Lauraine E. Lancet Oncol; 2018 Aug; 19(8):1126-1134. PubMed ID: 30026002 [Abstract] [Full Text] [Related]
13. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design. Poveda AM, Davidson R, Blakeley C, Milner A. Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234 [Abstract] [Full Text] [Related]
14. Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial. Liu J, Yin R, Wu L, Zhu J, Lou G, Wu X, Zhou Q, Gao Y, Kong B, Lu X, Wang J, Chen Y, Cheng Y, Wang Y, Lu W, Li W, Ma X, Hsu K. Asia Pac J Clin Oncol; 2022 Dec; 18(6):714-722. PubMed ID: 35357078 [Abstract] [Full Text] [Related]
16. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy. Zhang N, Zheng H, Gao Y, Shu T, Wang H, Cai Y. J Ovarian Res; 2024 Mar 05; 17(1):55. PubMed ID: 38444005 [Abstract] [Full Text] [Related]
20. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study. Trillsch F, Mahner S, Ataseven B, Asher R, Aryal N, Dubot C, Clamp A, Penson RT, Oza A, Amit A, Huzarski T, Casado A, Scambia G, Friedlander M, Colombo N, Fujiwara K, Sonke GS, Denys H, Lowe ES, Lee CK, Pujade-Lauraine E. Gynecol Oncol; 2022 Apr 05; 165(1):40-48. PubMed ID: 35115180 [Abstract] [Full Text] [Related] Page: [Next] [New Search]